Harpoon Therapeutics, Inc. Common Stock

HARP

市值 US$4.92億

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Harpoon Therapeutics, Inc. (NasdaqCM: HARP) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Harpoon will receive $23.00 in cash for each share of Harpoon that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.

Shares of Harpoon Therapeutics Inc. (HARP) more than doubled Monday after Merck & Co. (MRK) agreed to buy the cancer drug researcher for about $680 million.

Pharmaceutical company Merck (MRK) will acquire cancer drugmaker Harpoon Therapeutics (HARP) in a deal valued at $680 million. The closing of the acquisition is currently pending, awaiting approval from Harpoon shareholders.

MILWAUKEE , Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Harpoon (Nasdaq: HARP)  for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join the https://www.ademilaw.com/case/harpoon-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Harpoon Therapeutics, Inc. (NASDAQ: HARP) to Merck for $23.00 per share in cash is fair to Harpoon shareholders. Halper Sadeh encourages Harpoon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Harpoon and its b.

Harpoon Therapeutics (NASDAQ: HARP ) stock is rocketing higher on Monday after Merck (NYSE: MRK ) announced plans to acquire the company. Merck is offering $23 per share for HARP stock.

Merck has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.

Merck & Co said on Monday it would buy cancer drug developer Harpoon Therapeutics for about $680 million, reinforcing its oncology portfolio with immunotherapies.

RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. “At Merck, we continue to enhance our oncology pipeline through strategic acquisitions that compl.

Merck & Co Inc (NYSE:MRK) is close to acquiring Harpoon Therapeutics Inc, a cancer drug developer, for about $700 million to bolster its oncology portfolio. The proposed deal, which could value Harpoon at $23 per share, aligns with Merck's strategy to seek new growth opportunities as its top-selling cancer drug Keytruda faces future pricing pressures.